Trials / Completed
CompletedNCT00174564
EXIBIT: Oxaliplatin in Biliary Tract Cancer
A Multicentre Phase II Trial of Gemcitabine and Oxaliplatin (GEMOX) in Patients With Biliary Tract Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 67 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective is to evaluate the efficacy of the GEMOX treatment as 1st line therapy in patients with advanced biliary tract cancer based on response rate measured by the RECIST unidimensional criteria. Secondary objectives are : Progression free survival, overall survival and safety.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | oxaliplatin |
Timeline
- Start date
- 2003-04-01
- Primary completion
- 2006-09-01
- Completion
- 2006-09-01
- First posted
- 2005-09-15
- Last updated
- 2012-02-17
Source: ClinicalTrials.gov record NCT00174564. Inclusion in this directory is not an endorsement.